Shares of Lantheus (LNTH) plummeted 16.33% in early trading on Wednesday, following the release of disappointing first-quarter 2025 financial results and reduced full-year guidance. The medical imaging and diagnostics company's earnings report fell short of analyst expectations, triggering a significant sell-off.

Lantheus reported adjusted earnings per share (EPS) of $1.53 for Q1 2025, missing the IBES estimate of $1.66. Revenue for the quarter came in at $372.8 million, also falling short of the projected $379 million. Despite generating a robust free cash flow of $98.8 million, the earnings miss has raised concerns about the company's growth trajectory.

Adding to investor worries, Lantheus trimmed its 2025 adjusted earnings guidance to $6.60 to $6.70 per share from the previous $7 to $7.20. The company also narrowed its annual revenue guidance to $1.55 billion to $1.59 billion from $1.55 billion to $1.61 billion. This reduction in outlook, coupled with the Q1 underperformance, has significantly dampened investor sentiment, leading to the sharp decline in stock price. As the market digests this financial update, all eyes will be on Lantheus' management for strategies to address the shortfall in the coming quarters.